Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dynamic Biotech & Genome Powershares (PBE) AMEX

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fund basics

See More

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.61 +2.87%
on 12/30/16
42.05 -5.54%
on 01/11/17
-1.11 (-2.72%)
since 12/20/16
3-Month
35.64 +11.45%
on 11/03/16
44.42 -10.58%
on 11/15/16
+0.41 (+1.04%)
since 10/20/16
52-Week
34.02 +16.75%
on 02/11/16
44.42 -10.58%
on 11/15/16
-1.05 (-2.58%)
since 01/20/16

Most Recent Stories

More News
Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Healthcare ETFs Are Latest Victim to Trump

Healthcare stocks, especially the biotech segment, and related exchange traded funds plunged Wednesday after President-elect Donald Trump singled out the rising drug prices at a press conference. The healthcare...

Biotech ETFs Slumping on Q3 Results

ETFs having significant allocation to biotech stocks are in focus given lackluster Q3 results

Biotech ETFs Slumping on Q3 Results

ETFs having significant allocation to biotech stocks are in focus given lackluster Q3 results

4 Frightful ETFs of This Year

Inside four heavily losing ETFs in the year-to-date frame.

4 Frightful ETFs of This Year

Inside four heavily losing ETFs in the year-to-date frame.

Inside the Recent Surge in Biotech ETFs

What caused biotech ETFs to tack on solid gains on September 12.

Inside the Recent Surge in Biotech ETFs

What caused biotech ETFs to tack on solid gains on September 12.

M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound

A large acquisition and favorable results from a drug trial helped biotechnology and pharmaceutical sector-related exchange traded funds rally on Monday. Among the best performing ETFs of Monday, the PowerShares...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Fund Summary

The PowerShares Dynamic Biotechnology & Genome Portfolio seeks investment results that correspond generally to the price and yield (before the Fund's fees and expenses) of an equity index called the Dynamic Biotechnology & Genome Intellidex Index (the "Underlying Intellidex"). The Underlying Intellidex...

See More

Support & Resistance

2nd Resistance Point 40.18
1st Resistance Point 39.95
Last Price 39.72
1st Support Level 39.56
2nd Support Level 39.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.